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Ankle injuries are one of the most common reasons to seek 
medical attention, with an estimated 1 million ankle injuries 
occurring per year.5,28 Osteochondral lesions of the talus 
(OCLTs) have been reported to occur at an incidence of 
0.1% of all talus fractures, though in a population of mili-
tary recruits analyzed over the course of 10 years, a more 
frequent occurrence was noted at 27 OCLTs per 100 000 
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Abstract
Background: Conventional methods are not suitable for difficult to treat osteochondral lesions of the talus (OCLTs). The 
role of particulated juvenile allograft articular cartilage implantation is not well elucidated for long-term patient outcomes.
Methods: Thirteen patients with difficult-to-treat OCLTs underwent arthroscopy-assisted implantation of particulated 
juvenile articular cartilage graft into defects from 2010 to 2012 by the same surgeon. “Difficult to treat” was defined as 
having at least 3 of the following features or 2 if both variables described lesion characteristics: (1) lesions size of 107 mm2 
or greater, (2) shoulder lesions, (3) patients who failed microfracture, (4) patient aged ≥40 years, or (5) patient body mass 
index (BMI) >25. Patients were evaluated using physical examination, patient interviews, and outcome score measures. 
Patients had follow-up at 2 years, 4 years, and between 6 and 10 years at their most recent follow-up. Differences in 
functional outcome scores were compared before and after surgery.
Results: Patients (age: 46.5 ± 11.8 years, BMI: 28.5 ± 6.1) had, on average, most recent follow-up of 8.0 years (range 72-
113 months). Average visual analog scale for pain score decreased for patients by 3.9 points (95% confidence interval [CI] 
2.18-5.60), when compared to preoperative assessment. Foot and Ankle Ability Measure (FAAM) Activities of Daily Living 
(ADL) and Sports subscale scores also improved from 46.5 to 80.9 (95% CI 21.35-47.43), and from 18.8 to 57.9 (95% CI 
21.05-57.10), respectively. Short Form–36 Health Survey physical component scores showed significant improvement by 
an average of 45.5 points (95% CI 32.42-58.50). American Orthopaedic Foot & Ankle Society Ankle-Hindfoot Scale scores 
improved from 55.2 to 80.3 (95% CI 12.459-37.741).
Conclusion: These results demonstrate positive patient-reported long-term outcomes for a cohort of patients with 
difficult OCLTs, followed over the course of 6-10 years after treatment with arthroscopy-assisted particulated juvenile 
articular cartilage implantation.
Level of Evidence: Level II, prospective cohort study.
Keywords: talus, osteochondral defects, talar osteochondral lesions, microfracture, juvenile articular cartilage implantation
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persons per year.34,42 Traumatic ankle injuries are the major 
source of osteochondral lesions or defects in the talus, with 
up to 50% of traumatic ankle sprains and fractures associ-
ated with talar lesions.47 Repetitive microtrauma, degenera-
tive joint arthropathy, and metabolic disarrangements 
contributing to osteonecrosis are all secondary etiologies of 
OCLTs described.15,31,35,46,58
Distal fibular fractures, complete deltoid ligament rup-
tures, and chronic lateral ligament instability have the 
highest concomitant association with talar lesions (range, 
55%-100%).27 These articular cartilage injuries, as distinct 
pathologies or summated, can have a significant impact on 
occupation as well as activities of daily living, with a 
range of presentations from asymptomatic to chronic pain 
and disability.25,43,48,51
Initial operative management typically consists of 
arthroscopic removal of loose bodies and bone marrow 
stimulation (BMS) techniques such as debridement, micro-
fracture, abrasion chondroplasty, curettage, and antegrade 
or retrograde drilling, having demonstrated overall positive 
results, particularly for smaller lesions.37,49,55 However, it is 
widely accepted that this method leads to fibrocartilage 
with predominantly type 1 collagen that can lead to unpre-
dictable histologic structure, wear properties, and ulti-
mately, unpredictable longevity compared with normal 
hyaline cartilage.22,37
Larger lesions or those with underlying subchondral bone 
involvement, in the form of cystic changes or sclerosis, 
require either osteochondral allograft or autologous chon-
drocyte implantation.23,36,40 Traditionally, the minimum 
lesion area for these procedures was set at 150 mm2 given 
the effectiveness of BMS techniques for smaller lesions; 
however, more recent studies have demonstrated these tech-
niques may in fact be useful for lesion sizes as small as 107 
mm2.12,44,53,59 Beyond size, other risk factors that should be 
considered when choosing cartilage restoration over BMS 
include: medial lesions,57 shoulder lesions,1,16,24,29,57 pres-
ence of a cyst,16,29 ankle instability,33 repeat surgery,16 patient 
age greater than 40 years,18,57 and body mass index.18
Osteochondral autograft transfer system has been 
accepted as the primary method of treatment for these more 
difficult defects; however, complications such as residual 
knee pain from the graft site, a multiday procedure, and the 
necessity for a malleolar osteotomy have made this tech-
nique not devoid of its own issues.32,38,50 Donor site harvest-
ing in mosaicplasty has noted as high as a 19.6% rate of 
morbidity of the donor site for knee-ankle, more than triple 
that of knee-knee.4,7 Furthermore, a systematic review con-
ducted by Bull et al13 observed for patients who had a 
biplane medial malleolar chevron osteotomy, 30% had mea-
surable incongruence at the joint line whereas 6% had non-
union observed by radiograph. These complication rates are 
difficult to neglect. Advocating for an alternative interven-
tion devoid of these pitfalls is merited.
One option to consider is allograft techniques, which can 
be performed entirely arthroscopically, in the course of a 
single operation, and do not require a donor site.52 
Particulated juvenile articular cartilage—a prepackaged 
articular cartilage allograft from young donors (ages less 
than 13 years) with viable chondrocytes and hyaline carti-
lage—has demonstrated good results in microfractures, 
refractory lesions, as well as larger lesions unlikely to 
respond to BMS techniques.8,14,17,45 Short to midterm fol-
low-up of patients with particulated juvenile articular carti-
lage treatment has shown improvement in ankle pain and 
disability as well as MRI data suggesting that defect filling 
is possible and persists for at least 2 years.17,19,21,26,30 Several 
of these reports concluded that this allograft had significant 
potential but that further trials needed to be conducted to 
fully elucidate its uses and indications. Similarly, no institu-
tion has published mid- to long-term follow-up results for a 
population treated by particulated juvenile articular carti-
lage allograft transplantation.
Therefore, the purpose of the current study was to evalu-
ate the long-term quality of life metrics of patients treated 
with particulated juvenile allograft cartilage implantation 
for difficult to treat OCLTs. The authors hypothesize a sta-
tistically significant improvement in patient self-assessment 
metrics of ankle mobility, degree of pain, and functional 
capability after arthroscopy-assisted implantation of partic-
ulated juvenile articular cartilage graft when compared to 
preoperative scores.
Methods
Patient Population, Study Selection, and 
Correspondence
Following approval by our institutional review board, a 
total of 15 patients were included in the study considered as 
having a difficult to treat OCLT bone. “Difficult to treat” 
was defined as having at least 3 of the following features or 
2 if both described lesion characteristics specifically: (1) 
lesions size of 107 mm2 or greater (measured arthroscopi-
cally), (2) shoulder lesions, (3) patients who failed micro-
fracture, (4) patient age ≥40 years, or (5) patient body mass 
index >25. These variables were selected based on prior 
literature suggesting each as (1) a risk factor for worsening 
lesion progression or (2) a poor prognosticator for improve-
ment after operative intervention.1,16,18,24,29,57 Evaluation 
before surgery included physical examination, patient inter-
views, and patient-reported outcome scores (PROMs), 
including visual analog scale for pain (maximum score: 10), 
Short Form–36 Health Survey physical and mental compo-
nent summaries (SF-36 PCS and MCS, respectively; maxi-
mum score: 100), Foot and Ankle Ability Measure (FAAM) 
with Activities of Daily Living (ADL, maximum score: 
100) and Sports subscales (maximum score: 100), and 
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American Orthopaedic Foot & Ankle Society (AOFAS) 
Ankle-Hindfoot Scale (maximum score: 100).
After having completed preoperative score assessment 
reports, these patients underwent arthroscopic implantation 
of particulated juvenile articular cartilage allograft tissue 
(DeNovo NT; Zimmer, Warsaw, IN) by the senior author 
(C.C.) between November 2010 and May 2012. OCLTs were 
further characterized intraoperatively by location as well as 
shoulder lesions. Patients with (1) arthroscopic lesion mea-
surements of at least 107 mm2 or (2) a failed previous surgery 
for a microfracture were included in the final analysis.
Operative Technique
The patient is positioned supine. After induction of general 
anesthesia, the ankle is placed in an ankle distractor. The 
procedure begins with a diagnostic ankle arthroscopy. The 
location and size of the defect is noted, and any concomitant 
pathologies are addressed. All transplantations were per-
formed arthroscopically without the use of a malleolar oste-
otomy. In order to maximize visibility and accessibility, the 
ankle is ranged and portal placement may be re-evaluated 
and repositioned accordingly. Lesion size was measured 
intraoperatively by the attending surgeon before proceed-
ing. A probe with graduations every 1.0 mm was used to 
measure the lesion at its widest point in 2 planes under 
direct arthroscopic visualization. The remainder of the pro-
cedure is similar to the techniques described by Kruse et al30 
and Cerrato et al.14
With inflow of water suspended and the lesion appearing 
dried, a thin layer of Baxter TISSEEL fibrin glue (Deerfield, 
IL) is delivered with a syringe into the base of the lesion. 
The particulated juvenile articular cartilage is loaded retro-
grade into an ankle arthroscope canula on the back table. 
The graft is provided as particulated pieces, each measuring 
approximately 1 mm3, suspended in a preservation solution. 
Each package includes enough to cover a defect measuring 
250 mm2. Multiple packages may be used for larger lesions.
The allograft is then placed in the lesion aiming to fill the 
defect to the level of the surrounding articular cartilage by 
using the arthroscope cannula trochar to carefully push the 
allograft into the defect. Next, a Freer Elevator is used to 
impact the graft to seat the particles flush with the surround-
ing native articular cartilage. Another layer of fibrin glue is 
delivered over the graft with 5 minutes given to dry. The 
portals are closed in a standard fashion. For patients with 
cystic OCD, the lesion was debrided to down to bleeding 
bone, and/or multiple channels were made in the base with 
a small microfracture pick. Bone graft from the calcaneus 
was used to fill the defect up to the adjacent subchondral 
bone, delivering it in a similar manner as described for the 
allograft. A thin layer of fibrin glue was then placed over the 
bone graft and the allograft cartilage was placed over that. 
The steps of particulated juvenile cartilage allograft implan-
tation described here are pictorially depicted in Figure 1.
In the case of an uncontained lesion, there was typically 
a small rim of medial talar cartilage and subchondral bone 
that held some of the bone graft in place. A freer elevator 
Figure 1. Arthroscopic particulated juvenile cartilage allograft implantation. (A) Osteochondral lesion debrided to a stable border. 
(B) Fibrin glue placed at the base of the lesion after the fluid turned off and the area dried. (C) Graft administered onto the lesion. (D) 
Graft contoured into the lesion. (E) Additional layer of fibrin glue added to cover the graft. (F) Final lesion filled with the graft.
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was then used to contour the shape of the “corner” of the 
talus as best as possible. The allograft cartilage was then 
placed only on the superior surface of the talar dome.
Postoperatively, the patient is initially placed in a short 
leg splint and kept nonweightbearing for a total of 4 weeks. 
The patient is transitioned to a removable CAM boot at 2 
weeks and is started on active and passive range of motion 
exercises, progressing to weightbearing as tolerated 
between 4 and 8 weeks. At 8 weeks, the patient is allowed 
to begin strength exercises and light activity, weaning off 
boot as tolerated. Return to sport or more strenuous activity 
is allowed as tolerated after 4-6 months.
Clinical Evaluation and Data Collection
Study participants were evaluated prospectively at 6 weeks, 
12 weeks, 6 months, and at 2 years, 4 years, and 8 years 
with the same evaluation metrics mentioned in preoperative 
patient recruitment. Only evaluations collected at 2, 4, and 
8 years after surgery were used in this analysis.
Statistical Analysis
This study enrolled consecutive patients undergoing particu-
lated juvenile articular cartilage implantation by a single sur-
geon. Therefore, statistical power was not considered during 
subject enrollment. The confidence interval (CI) for 2 inde-
pendent samples was used to compare mean outcome scores, 
with significance set at a CI of 95% with minimum range 
greater than 1. For comparison of patient outcome scores 
between postoperative follow-up dates, an analysis of vari-
ance was performed with post hoc analysis of 2-sample mean 
t test if significance was derived. Alpha value was set at 0.05 
for significance. The minimum clinically important differ-
ence (MCID) in scores was determined as the preoperative 
SD for each PROM utilized. The MCID is defined as “a sta-
tistical model that attempts to define the smallest change in a 
treatment outcome that a patient would identify as impor-
tant.”6 Although several methodologies for calculating the 
MCID have been utilized,54 the authors chose a higher thresh-
old of a full rather than 0.5 SD given the small sample size 
and likely nonparametric distribution of this study’s cohort. 
All data were analyzed using SPSS software (version 20; 
IBM, Armonk, NY), Microsoft Excel (Microsoft Corporation, 
Redmond, WA), and Stata, version 16.1 (College Station, 
TX). Graphical depictions were created with Prism version 
8.4 (GraphPad Software Inc, San Diego, CA).
Results
Patient Demographics
Two patients were ultimately excluded because of inadequate 
follow-up or no correspondence at all. The most recent fol-
low-up for all patients averaged to 97.8 ± 26.6 months 
(range, 72-120 months). The average age at the time of sur-
gery was 46.5 ± 11.8 years (range, 18-61 years), with a male-
to-female ratio of 8:5. The average body mass index was 28.5 
± 6.1 (range, 20.6-36.9). The majority of patients reported a 
preceding traumatic injury to the ankle (n = 10, 76.9%).
The mean lesion size measured on arthroscopy for all 
patients was 151 ± 53 mm2 (range: 70-260 mm2), whereas 
the average lesion size for patients who had not undergone 
previous surgery was 155 ± 38 mm2 (range: 120-216 mm2). 
Four patients (30.8%) had undergone a previous surgery for 
microfracture of the lesion of interest with persistent or 
recurrent symptoms. Six (46.2%) participants required an 
additional procedure at the time of implantation, in particu-
lar, bone grafts. Patient demographics, operative histories, 
and OCLT descriptions are listed in Table 1.
Functional Outcome Scores
The average visual analog scale for pain score decreased for 
patients by 3.9 ± 2.8 points (95% CI 2.18-5.60), when com-
pared to preoperative assessment. FAAM ADL and Sports 
scores also showed improvement by 34.4 ± 21.8 (95% CI 
21.35-47.43) and 39.0 ± 20.7 (95% CI 21.05-57.10), 
respectively. SF-36 physical component summary scores 
showed improvement by an average of 45.5 ± 20.7 points 
(95% CI 32.42-58.50), whereas mental component scores 
improved by 26.0 ± 21.9 points (95% CI 12.47-39.53). 
Average preoperative AOFAS score improved by 25.1 ± 
17.2 (95% CI 12.44-37.72).
Between postoperative evaluation dates, there was no 
significant difference in patient-centered survey scores 
using the numbers available, except for SF-36 PCS 
between the 2-and 4-year and the 2-and 8-year follow-up 
(2-year = 50.5 vs 4-year = 86.7, 8-year = 81.2; P value 
<.001 for both) and SF-36 MCS between 2- and 4-year 
and the 2- and 8-year follow-up (2-year = 43.7 vs 4-year 
= 85.0, 8-year = 78.9; P value < .001 for both). These 
results are summarized in Table 2, with patients with 
lesions greater than 150 mm2 demonstrating comparable 
results. Averaged patient functional outcome scores 
depicted over time is shown in Figure 2.
The MCID was achieved by 11 (84.6%) patients for 
visual analog scale score, 11 (84.6%) patients for FAAM 
ADL score, 13 (100%) patients for FAAM Sports score, 12 
(92.3%) patients for AOFAS score, 12 (92.3%) patients for 
SF-36 PCS score, and 8 (61.5%) patients for SF-36 MCS. 
All but 2 patients achieved the MCID for the majority of 
PROMs (Table 1).
Complications
There were no intraoperative or perioperative complica-
tions observed. A postoperative MRI at 2-year follow-up for 
1 patient demonstrated integration of bone graft with some 
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Additionally, another patient did show persistent pain 
within the first year after surgery, requiring second-look 
arthroscopy with debridement. On examination, the patient 
was noted to have partial delamination of the graft as shown 
in Figure 4. An osteochondral autograft transfer system was 
considered, but he eventually improved and opted out of 


















1 6 0 65 98 46 75 67 93 43.7 95 30.4 84
2 7 3 35 67 11 32 41 60 24.3 75.0 68.2 84
3 6 1 39 92 25 89 70 100 32.6 95.0 47.2 92
4 8.5 4 44.0 82 7.1 57 36.0 72 25.0 90 65.6 92
5 5 2 84 95 35 90 67 95 38.7 100 56.3 60
6 5 2 45 71 29 61 42 82 33.9 80 54.4 80
7 6 8 49 62 18 39 53 64 32.7 30 59.4 64
8 7 3 24 74 4 18.0 36 67 27.6 55 37.6 88
9 10 6 62 46 7 25 67 54 36.9 60 50.4 92
10 10 1 48 98 25 78 51 100 50 100 88 72
11 8 1 36 100 29 100 70 100 30 100 92 100
12 6 5 37 79 4 21 77 77 35.7 65 32.4 60



























Abbreviations: ADL, activities of daily living; AOFAS, American Orthopaedic Foot & Ankle Society; FAAM, Foot and Ankle Ability Measure; MCS, 
mental composite summary; PCS, physical composite summary; Preop., preoperative; SF-36, Short Form–36 Health Survey; VAS, visual analog scale.
*Mean scores (SD) between preoperative and latest follow-up showed statistically significant difference (95% confidence interval does not contain 
the value 1).
Figure 2. Long-term patient functional outcome scores assessed preoperatively and postoperatively at the 2-year, 4-year, and 8-year 
follow-up.
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additional operative intervention. There were no complica-
tions associated with calcaneal bone grafting.
Discussion
This small cohort study showed that the use of arthroscopy-
assisted particulated juvenile cartilage allograft implanta-
tion of talar osteochondral lesions is an effective single 
procedure treatment modality for the treatment of difficult 
to treat lesions, primarily moderate sized lesions or patients 
who failed microfracture. These results demonstrate clini-
cally positive long-term outcomes for a cohort of patients 
followed over the course of 6-10 years, as assessed by 
patient-reported survey outcomes.
This study’s findings showed comparable results to oth-
ers who have analyzed OCLTs treated with allograft trans-
plantion.9,10,19,26,30,45 Bleazey et al9 followed a cohort of 7 
patients 6 months after surgery, who demonstrated clini-
cally significant improvements in self-reported pain and 
activity scale scores. Coetzee et al17 followed a cohort of 24 
patients for approximately 16 months and reported that 
78% of patients had AOFAS scores demonstrating good to 
excellent scores. In this study, all patients achieved the 
MCID for the majority of PROMs assessed except for 2 
patients, which had little to no improvement in their postop-
erative scores.
When analyzing patient outcome functional scores 
relative to different time points, there was a clinically sig-
nificant (not statistically significant) peak at the 4-year 
mark relative to 8-year follow-up. This begs the question 
of if the longevity of the graft or its maximal benefits may 
reach a limit before patients decompensate again. This 
could be explored via MRI or second-look arthroscopy to 
observe continuous graft incorporation. It should be 
noted, however, that in vitro studies of osteochondral 
allograft incorporations have noted how allografts have 
significantly lower levels of cartilage proteoglycans along 
with depleted metalloproteinases compared with normal 
patient defective cartilage, which can in fact contribute to 
longer-term stability in vivo.20 Our participants’ mildly 
Figure 3. Magnetic resonance imaging (MRI) of same patient before and after operation. (A) Preoperative MRI of patient with a large 
osteochondral lesion of the talus, (B) postoperative MRI 2 years after particulated articular cartilage allograft transplantation.
Figure 4. Second-look arthroscopy of patient 1 with persistent 
pain showing partial graft delamination.
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worsening functionality and pain may therefore be better 
explained by surrounding tissue degradation, preclinical 
osteoarthritis, or an entirely separate, concomitant liga-
mentous or bone injury.
The findings of this study, overall, suggest that particu-
lated juvenile articular cartilage allograft transplantation is 
a safe and effective treatment option. The one additional 
patient who did require second-look arthroscopy with 
debridement of the graft site did have improvement in terms 
of his symptoms and pain with functional and pain scores. 
For this particular patient, it raises the question of whether 
graft hypertrophy is also a potential problem with allograft 
cartilage implantation; second-look arthroscopy with 
debridement was also warranted for 7 of 33 patients in 
Heida et al’s26 series, with at least 2 patients definitively 
noted for graft hypertrophy. As reported in the systematic 
analysis performed by Saltzman et al,45 revision to an open 
osteochondral allograft with medial malleolar osteotomy is 
infrequent, with only 1 reported in their review of 4 studies. 
The predominant reason for reoperation was hardware 
removal (medial malleolar osteotomy hardware). As far as 
this team is aware, no other studies to date have reported 
need for revision to osteochondral allograft.
In discussing graft incorporation, Saltzman et al45 
reported excellent clinical outcomes in their relatively 
short-term follow-up, despite MRI-proven persistent sub-
chondral edema and minimal change in lesion appearance 
up to 2 years postoperatively. They hypothesized that 
given the promising clinical results, the consolidation 
process may lag and take several years to show on 
advanced imaging. It is important to note that alternative 
treatments such as autologous chondrocyte implantation 
have shown integration on advanced imaging at up to 5 or 
10 years postoperatively.23 Incorporation was observed 
by MRI at close to 2 years postoperatively for our 1 
patient, which warranted additional imaging for a non-
related ankle complaint (Figure 3).
Lesion size alone has been shown to correlate with clini-
cal outcomes. A systematic review by Ramponi et al44 
including 25 studies with 1868 ankles demonstrated the 
critical lesion size warranting BMS is for lesion sizes less 
than 107.4 mm2. Autologous chondrocyte implantation also 
has a recommended critical size limitation of less than 400 
mm2. Notably, a recent study by Yasui et al56 showed that 
MRI often overestimated lesion size when compared to 
measurements found intraoperatively and should also be 
considered when deciding which modality to employ. In 
this report, patients with lesion sizes up to 260 mm2 achieved 
the MCID in the majority of scores assessed, suggesting 
improved outcomes.
Overall, several treatment options have been described 
for moderate-sized and/or difficult osteochondral lesions of 
the talus without a clear-cut consensus on the best treatment 
strategy. The hypothetical advantage to using juvenile 
allograft cartilage implantation is that it can be performed 
as a single-stage procedure that does not require harvesting 
the patient’s own tissue, thereby obviating the risk of donor 
site complications. Furthermore, juvenile chondrocytes 
have been shown to produce more extracellular matrix pro-
teins (GAGs), synthesize higher levels of type II collagen, 
and exist in a higher density in articular cartilage compared 
with adult chondrocytes.2,10,39 Additionally, it confers 
through its properties a chance to re-create hyaline cartilage 
through an arthroscopic procedure without the morbidity of 
an open surgery.11 Particulated juvenile articular cartilage 
allograft may also be a reliable treatment option in patients 
who have undergone previously failed microfracture. 
Although there may be a theoretical concern for fibrocarti-
lage formation after a bone marrow stimulating treatment, 
all 4 patients in this study who had previous surgery had 
good to excellent outcomes, with only 1 requiring addi-
tional debridement.
Though many benefits of allograft transplantation have 
been discussed, this intervention is not without limitation. 
In addition to its expensive price and reduced availability 
in certain geographical regions, a recent systematic review 
by Aldawsari et al3 found in radiographic imaging, a lack 
of repair in subchondral bone and lamina in patients treated 
with juvenile allograft transplantation, with concomitant 
satisfactory functional outcome scores reported. This can 
imply that although patients achieve improved functional 
outcome scores after allograft transplantation, at the cellu-
lar level, full restoration of the normal hyaline articular 
cartilage is unlikely. Furthermore, for the 6 patients that 
had a concomitant calcaneus bone graft, donor site morbid-
ity could present as a complication; nevertheless, reports 
are infrequent. O’Malley et al41 observed moderate to 
severe complications after percutaneous calcaneal auto-
graft bone harvest in 1.4% (3/393) of patients, whereas 
knee donor-site morbidity for knee-ankle mosaicplasty has 
been cited at 17.2%.4 Although these studies’ methodology 
for grafting were not identical, harvesting using the calca-
neal bone appears to be a reasonably safe option.
The strengths of this study include the use of a single-
surgeon cohort with a longer period of follow-up than any 
other institution has previously reported. This study also 
reports on a specific cohort of patients with poor prognos-
tic factors. Contrarily, notable limitations include that 
population prospectively followed lacked 1:1 matching of 
patients to controls nor comparison to other interventions. 
Lesions were measured arthroscopically, which may not 
adequately describe the true lesion size given (1) how 
lesion edges are defined is not standardized and (2) lesion 
size likely is widened after debridement intervention.56 
Additionally, several patients had concomitant procedures 
performed, which does not necessarily attribute all out-
come measure values to the single allograft. Postoperative 
and long-term follow-up imaging was not obtained for 
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most patients. Therefore, these results of patient-reported 
outcomes should not be extrapolated to suggest restoration 
of the defect nor can comment on the status of the carti-
laginous tissue. The presence or absence of ankle arthritis 
also could not be commented on. Furthermore, 2 of 15 
patients were lost to follow-up whereas assessment scores 
were predominantly self-reported by patients, which 
intrinsically presents reporting bias. The AOFAS score in 
particular has not been validated as a true outcome metric. 
To remove this subjectivity, a follow-up to the evaluation 
of this technique would perhaps involve imaging of all 
lesions to fully assess graft incorporation and evaluation 
for potential osteoarthritis. Several methodologies have 
been suggested in calculating the MCID with unclear dif-
ferentiation in which is the most effective. A post hoc 
power analysis for each outcome of interest demonstrated 
a study power of at least 95%. With such large effect sizes 
seen for all outcomes, the 13 patients were an adequate 
sample size to be sufficiently powered to detect a statisti-
cally significant difference from preoperative to last fol-
low-up. Ultimately, a larger-scale randomized controlled 
trial is needed to validate this as a superior treatment 
option as well as to further elucidate the risk factors for 
failure.
Conclusion
Patients with high-risk OCLTs, a subgroup underexamined 
and characterized by inferior outcomes, remain a challeng-
ing clinical entity to treat successfully as is evident by the 
multitude of modalities used to manage this pathology. 
Although several operative options exist, these results sug-
gest juvenile cartilage particulated allograft may be a 
favorable selection. Understanding the longevity of this 
intervention can better aid clinicians in deciding if this 
treatment option is appropriate for patients, while also 
financially pragmatic. In sum, our findings suggest 
allograft transplantation is an effective long-term treatment 
option for patients with talar osteochondral lesions and 
should be a part of the orthopedics’ armamentarium.
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